empagliflozin
boehringer ingelheim
['empa-kidney']
large empa-kidney meta-analysis highlights safety/efficacy of #sglt2 inhibitors in reducing risk of kidney disease progression, acute kidney injury, cv death &amp; #heartfailure hospitalization in patients w/ #ckd or hf, irrespective of #diabetes status #aha22 
Official account of the American College of Cardiology. Join us to transform cardiovascular care & improve heart health. Find us: @JACCJournals @Cardiology